Galecto, Inc. (GLTO)
Evaluation: Based on all recent filings, financial statements, and news.
See full evaluationAsk a question about Galecto, Inc. (GLTO)
Go deeper and ask any question about GLTO
Company Performance
Current Price
as of Sep 13, 2024$12.93
P/E Ratio
N/A
Market Cap
$16.14M
Description
Galecto, Inc. is a clinical-stage biotechnology company, which engages in developing novel small molecule therapeutics that are designed to target the biological processes that lie at the heart of cancer and fibrotic diseases. The firm is also involved in the development of small molecule inhibitors of galectin-3, lysyl oxidase-like 2, and LOXL2. The company was founded by Ulf Jörgen Nilsson, Hakon Leffler, Tariq Sethi, and Hans Thalsgård Schambye in 2011 and is headquartered in Boston, MA.
Metrics
Overview
- HQBoston, MA
- SectorHealth Technology
- IndustryPharmaceuticals: Major
- TickerGLTO
- Price$12.93-8.62%
Trading Information
- Market Cap$16.14M
- Float81.16%
- Average Daily Volume (1m)480,703
- Average Daily Volume (3m)244,165
- EPS-$23.45
Company
- RevenueN/A
- Rev Growth (1yr)N/A
- Net Income-$5.34M
- Gross MarginN/A
- EBITDA MarginN/A
- EBITDA-$4.53M
- EV-$9.92M
- EV/RevenueN/A
- P/EN/A
- P/SN/A
Documents
SEC Filings
Factset Street Account